阿托伐他汀在感染性休克治疗中的应用效果和安全性分析 |
| |
引用本文: | 张静,;张素艳,;耿晓妍,;王爱田,;高景利,;李晓岚.阿托伐他汀在感染性休克治疗中的应用效果和安全性分析[J].中国基层医药,2014(15):2246-2248. |
| |
作者姓名: | 张静 ;张素艳 ;耿晓妍 ;王爱田 ;高景利 ;李晓岚 |
| |
作者单位: | [1]唐山市开滦精神卫生中心药剂科,河北省唐山063000; [2]唐山市开滦赵各庄医院内分泌;,河北省唐山063000; [3]唐山市开滦总医院超声科;,河北省唐山063000; [4]唐山市开滦总医院重症医学科,河北省唐山063000; |
| |
基金项目: | 基金项目:河北省唐山市科技研究与发展指导计划项目(13130213a) |
| |
摘 要: | 目的:探讨阿托伐他汀在感染性休克治疗中的应用效果及安全性。方法将67例感染性休克患者按随机数字表法分为治疗组34例和对照组33例,对照组采用常规药物治疗,观察组在对照组基础上加用阿托伐他汀。比较两组治疗前后患者炎性反应指标、细胞因子水平变化,多器官功能障碍综合征( MODS)病例数,28 d死亡病例数,不良反应发生情况。结果治疗组心率、呼吸频率、白细胞计数明显优于对照组,细胞因子改善水平显著优于对照组,差异均有统计学意义(t=4.181、3.622、4.879,均P<0.05);治疗组MODS发生率明显低于对照组(χ2=7.153,P<0.05);治疗组平均住院天数为(9.3±3.1) d,明显少于对照组的(12.4±3.3)d(t=3.964,P<0.05)。两组不良反应发生率差异有统计学意义(χ2=4.566,P<0.05);两组患者28 d病死率差异无统计学意义(χ2=3.345,P>0.05)。结论阿托伐他汀可以减轻感染性休克患者炎性反应程度,降低MODS发生率,对患者预后可能存在潜在益处,但仍需进一步临床研究加以证实。
|
关 键 词: | 休克 感染 阿托伐他汀 |
Analysis of the effect and safety of atorvastatin in the treatment of septic shock |
| |
Institution: | Zhang Jing, Zhang Suyan, Geng Xiaoyan , Wang Aitian , Gao Jingli , Li Xiaolan( Department of Pharmacy, Kailuan Mental Health Center, Tangs- han, Hebei 063000, China) |
| |
Abstract: | Objective To explore the clinical efficacy and safety of atorvastatin in the treatment of patients with septic shock.Methods 67 patients with septic shock were randomly divided into the treatment group (34 cases) and control group(33 cases).The control group was treated with conventional therapy ,and the observation group was administered with atorvastatin based on the control group .Before and after treatment ,the inflammatory index ,cytokines levels,the number of MODS cases,the number of deaths at 28th day,and the incidence of adverse reactions were com-pared between the two groups .Results The heart rate ,respiratory rate ,white blood cell count of the treatment group were significantly better than the control group ,the cytokines levels were significantly lower than the control group ,the differences were statistically significant (t=4.181,3.622,4.879,all P〈0.05).The incidence rate of MODS of treat-ment group was significantly lower than that of the control group (χ2 =7.153,P〈0.05).The average hospital stay of the treatment group was (9.3 ±3.1)d,which was significantly less than (12.4 ±3.3)d of the control group(t=3.964,P〈0.05).The incidence rate of adverse reaction in the treatment group was significantly lower than that of the control group(χ2 =4.566,P〈0.05).The 28 d mortality rate of the two groups had no significant difference (χ2 =3.345,P〉0.05).Conclusion Atorvastatin can effectively reduce the degree of inflammatory reaction in patients with septic shock ,decrease the incidence of MODS , and has potential benefits on the prognosis of patients , but still need to be further confirmed by clinical research . |
| |
Keywords: | Shock Infection Atorvastatin |
本文献已被 维普 等数据库收录! |
|